COVID-19 vaccines: Pfizer-BioNTech shot likely to foil mutant, new study shows
Study on South Africa strain suggests some re-infection threat
Naomi Kresge and Janice Kew, Bloomberg
Jan. 20, 2021
FacebookTwitterEmail
Pfizer Inc. and BioNTech SE built the case that their Covid-19 vaccine will protect against the new variant of the coronavirus that emerged in the U.K. with results of another lab trial.
Like previous work out of the University of Texas Medical Branch, the results published on Wednesday showed that antibodies in the blood of people who had been vaccinated were able to neutralize a version of the mutant virus that was created in the lab. The study was published on preprint server BioRxiv prior to peer review.